Christopher Snook discusses his dual role as Head of Group Country Management as well as Country President for Singapore, highlighting the importance of adhering to in-house as well as country-specific regulatory frameworks and the continued importance of Singapore to the global group.
We will continue to see Singapore in a very strategic context as far as the global Novartis group is concerned. It remains an investor-friendly environment and we have an extremely good relationship with the Singapore government
